A Study of Healthy Subjects to Assess the Effect of LY450139 on Amyloid Beta Peptide Production Rate and or Dose Response.
Status:
Completed
Trial end date:
2007-09-01
Target enrollment:
Participant gender:
Summary
To test that LY450139, a gamma-secretase inhibitor, will reduce the rate of newly synthesize
Amyloid Beta by determining the amount of newly synthesized 13C6 leucine-labeled Amyloid Beta
in lumbar cerebrospinal fluid from LY450139 treated subjects compared with placebo treated
subjects.